Giovanna Zinzalla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2936320/publications.pdf

Version: 2024-02-01

34	1,061	471477	454934
papers	citations	17 h-index	30 g-index

48	48	48	1870
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biophysical and Structural Methods to Study the bHLHZip Region of Human c-MYC. Methods in Molecular Biology, 2021, 2318, 21-43.	0.9	1
2	SWI/SNF subunit BAF155 N-terminus structure informs the impact of cancer-associated mutations and reveals a potential drug binding site. Communications Biology, 2021, 4, 528.	4.4	5
3	Structure of the BRK domain of the SWI/SNF chromatin remodeling complex subunit BRG1 reveals a potential role in proteinâ€“protein interactions. Protein Science, 2020, 29, 1033-1039.	7.6	17
4	Crystal Structures and Nuclear Magnetic Resonance Studies of the Apo Form of the c-MYC:MAX bHLHZip Complex Reveal a Helical Basic Region in the Absence of DNA. Biochemistry, 2019, 58, 3144-3154.	2.5	38
5	The structure of <scp>INI</scp>1/<scp>hSNF</scp>5 <scp>RPT</scp>1 and its interactions with the câ€<scp>MYC</scp>:<scp>MAX</scp> heterodimer provide insights into the interplay between <scp>MYC</scp> and the <scp>SWI</scp>/<scp>SNF</scp> chromatin remodeling complex. FEBS Journal, 2018, 285, 4165-4180.	4.7	22
6	A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Scientific Reports, 2018, 8, 10064.	3.3	85
7	Abstract 3952: Selective high affinity MYC-binding compound inhibits MYC-MAX interaction and MYC-dependent tumor cell growth. , 2018, , .		0
8	A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex. ChemBioChem, 2016, 17, 677-682.	2.6	21
9	Targeting MYC: is it getting any easier?. Future Medicinal Chemistry, 2016, 8, 1899-1902.	2.3	6
10	Targeting proteinâ€“protein interactions (PPIs) of transcription factors: Challenges of intrinsically disordered proteins (IDPs) and regions (IDRs). Progress in Biophysics and Molecular Biology, 2015, 119, 41-46.	2.9	27
11	Paving the way to targeting HECT ubiquitin ligases. Future Medicinal Chemistry, 2015, 7, 2107-2111.	2.3	6
12	The SWI/SNF Subunit INI1 Contains an N-Terminal Winged Helix DNA Binding Domain that Is a Target for Mutations in Schwannomatosis. Structure, 2015, 23, 1344-1349.	3.3	33
13	Tetracycline analogues with a selective inhibitory effect on HIF-1Î±. MedChemComm, 2014, 5, 923.	3.4	3
14	Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and Xâ€ray crystallography. FEBS Letters, 2013, 587, 833-839.	2.8	60
15	Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4719-4722.	2.2	45
16	Small-Molecule Inhibition of c-MYC:MAX Leucine Zipper Formation Is Revealed by Ion Mobility Mass Spectrometry. Journal of the American Chemical Society, 2012, 134, 19384-19392.	13.7	53
17	Molecular Dynamics Studies of the STAT3 Homodimer:DNA Complex: Relationships between STAT3 Mutations and Proteinâ€“DNA Recognition. Journal of Chemical Information and Modeling, 2012, 52, 1179-1192.	5.4	21
18	One-Pot Synthesis of Fused-Tetracyclic Scaffolds Employing a Lewis Acid Promoted Domino Reaction of Naphthoquinones. Synthesis, 2011, 2011, 2321-2333.	2.3	2

#	Article	IF	Citations
19	Abstract 1382: Use of polarized light spectroscopy (CD) to study STAT3 folding and STAT3:ligand interactions. , 2011, , .		0
20	Abstract 279: Use of GFP-STAT3Î²tc for EMSA analysis of protein-protein and protein-DNA interactions in tumorigenic signalling pathways. , 2011, , .		0
21	A novel small-molecule inhibitor of IL-6 signalling. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7029-7032.	2.2	16
22	113 Novel small-molecule inhibitors of Interleukin-6 (IL-6) signalling. European Journal of Cancer, Supplement, 2010, 8, 43.	2.2	0
23	Facile nucleophilic substitution at the C3a tertiary carbon of the 3a-bromohexahydropyrrolo[2,3-b]indole scaffold. Organic and Biomolecular Chemistry, 2010, 8, 5294.	2.8	28
24	Facile oxidation of electron-poor benzo[b]thiophenes to the corresponding sulfones with an aqueous solution of H2O2 and P2O5. Chemical Communications, 2010, 46, 2289.	4.1	20
25	Abstract 5454: Novel STAT3:STAT3 small-molecule inhibitors as potential anticancer agents. , 2010, , .		0
26	Targeting proteinâ€“protein interactions for therapeutic intervention: a challenge for the future. Future Medicinal Chemistry, 2009, 1, 65-93.	2.3	221
27	Naturalâ€Productâ€Like Spiroketals and Fused Bicyclic Acetals as Potential Therapeutic Agents for Bâ€Cell Chronic Lymphocytic Leukaemia. ChemMedChem, 2008, 3, 1922-1935.	3.2	34
28	Chemical Variation of Natural-Product-Like Scaffolds: Design, Synthesis, and Biological Activity of Fused Bicyclic Acetal Derivatives. Angewandte Chemie - International Edition, 2007, 46, 2493-2496.	13.8	51
29	Chemical variation of natural product-like scaffolds: design and synthesis of spiroketal derivatives. Organic and Biomolecular Chemistry, 2006, 4, 1977.	2.8	85
30	A Thymine-PNA Monomer as New Isocyanide Component in the Ugi Reaction: A Direct Entry to PNA Dimers. Synlett, 2004, 2004, 1044-1048.	1.8	18
31	A new ferrocene conjugate of a tyrosine PNA monomer: synthesis and electrochemical properties. Journal of Organometallic Chemistry, 2004, 689, 4791-4802.	1.8	35
32	Polymer-Supported Haloarene Chromium Dicarbonyl Isonitrile Complexes:â€‰ A Study of Their Synthesis and Reactivity. ACS Combinatorial Science, 2003, 5, 809-813.	3.3	12
33	Synthesis of Chiral Chromium Tricarbonyl Labeled Thymine PNA Monomers via the Ugi Reaction. Organic Letters, 2002, 4, 4341-4344.	4.6	61
34	Stereoselective hetero Dielsâ€“Alder reactions of chiral tricarbonyl (Î·6-benzaldehyde)chromium complexes. Tetrahedron: Asymmetry, 2001, 12, 2159-2167.	1.8	18